Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    Phenylpropanolamine and stroke: The study, the FDA ruling, the implications
    Tracey L. Mersfelder, PharmD
    Cleveland Clinic Journal of Medicine March 2001, 68 (3) 208-223;

    The FDA, after a recent study, asked manufacturers to pull dozens of products from the shelves.

  • You have access
    Making the most of cholesterol-lowering margarines
    Julie K. Avery, RD
    Cleveland Clinic Journal of Medicine March 2001, 68 (3) 194-196;

    These new “functional foods” reduce serum cholesterol and LDL levels modestly when used instead of regular margarine, butter, or oil. Are they worth it?

  • You have access
    Rare but serious adverse effects in commonly used drugs
    John D. Clough, MD
    Cleveland Clinic Journal of Medicine March 2001, 68 (3) 179;

    Some adverse effects come to light only after millions of people have taken a drug.

  • You have access
    In reply: Atrial septal defect repair (August 2000)
    Douglas S. Moodie, MD, MS
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 174;
  • You have access
    2000 Reviewers
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 153;
  • You have access
    New findings in multiple sclerosis: A message for primary care clinicians
    John D. Clough, MD
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 91;

    Every once in a while, a new finding transforms the diagnosis and treatment of a disease.

  • You have access
    Strategies to prevent progression of renal disease
    Phillip M. Hall, MD
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 143-151;

    Reviewing current theories of how renal disease develops and progresses and how to prevent or slow the process.

  • You have access
    A lung-transplant recipient with infiltrates
    Omar A. Minai, MD and Atul C. Mehta, MD
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 172-173;

    Questions and answers on the visible signs of diseases.

  • You have access
    Changing patterns of morbidity and mortality in HIV disease
    Leonard H. Calabrese, DO
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 105-111;

    With the success of highly active antiretroviral therapy (HAART) come new problems.

  • You have access
    The Mustt Trial
    Stephen Pavia, MD and Bruce L. Wilkoff, MD
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 113-129;

    Implantable defibrillators, but not antiarrhythmic drugs reduce the mortality rate in MI survivors at high risk.

Pages

  • Previous
  • Next
  • 1
  • …
  • 407
  • 408
  • 409
  • 410
  • 411
  • 412
  • 413
  • 414
  • 415
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire